Brokerages predict that PerkinElmer, Inc. (NYSE:PKI) will post sales of $1.20 billion for the current quarter, Zacks reports. Four analysts have provided estimates for PerkinElmer’s earnings, with the highest sales estimate coming in at $1.21 billion and the lowest estimate coming in at $1.19 billion. PerkinElmer posted sales of $652.40 million during the same quarter last year, which suggests a positive year over year growth rate of 83.9%. The business is scheduled to issue its next quarterly earnings results on Tuesday, May 4th.
According to Zacks, analysts expect that PerkinElmer will report full-year sales of $4.16 billion for the current year, with estimates ranging from $4.06 billion to $4.42 billion. For the next year, analysts forecast that the firm will post sales of $3.60 billion, with estimates ranging from $3.40 billion to $3.78 billion. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for PerkinElmer.
PerkinElmer (NYSE:PKI) last released its earnings results on Tuesday, February 2nd. The medical research company reported $3.96 earnings per share for the quarter, topping analysts’ consensus estimates of $3.01 by $0.95. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.22 billion. PerkinElmer had a return on equity of 21.57% and a net margin of 12.74%. The firm’s revenue for the quarter was up 68.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.35 earnings per share.
In related news, insider Daniel R. Tereau sold 2,047 shares of the company’s stock in a transaction on Monday, February 1st. The shares were sold at an average price of $147.07, for a total value of $301,052.29. Following the completion of the sale, the insider now directly owns 10,378 shares in the company, valued at $1,526,292.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Prahlad R. Singh sold 10,636 shares of the company’s stock in a transaction on Tuesday, January 5th. The stock was sold at an average price of $150.00, for a total transaction of $1,595,400.00. Following the completion of the sale, the insider now owns 50,537 shares of the company’s stock, valued at $7,580,550. The disclosure for this sale can be found here. Insiders sold 16,777 shares of company stock valued at $2,496,960 over the last quarter. 0.62% of the stock is currently owned by corporate insiders.
Large investors have recently modified their holdings of the stock. Anderson Fisher LLC bought a new stake in PerkinElmer in the third quarter worth $35,000. Duncker Streett & Co. Inc. bought a new stake in PerkinElmer during the third quarter valued at about $38,000. Liberty Wealth Management LLC bought a new stake in PerkinElmer during the fourth quarter valued at about $40,000. Optimum Investment Advisors bought a new stake in PerkinElmer during the fourth quarter valued at about $43,000. Finally, TFC Financial Management bought a new stake in PerkinElmer during the third quarter valued at about $52,000. Hedge funds and other institutional investors own 89.44% of the company’s stock.
Shares of NYSE PKI traded down $0.06 during trading on Friday, hitting $129.66. The company had a trading volume of 3,410 shares, compared to its average volume of 1,016,235. The company has a market cap of $14.52 billion, a P/E ratio of 35.25, a PEG ratio of 0.99 and a beta of 1.19. PerkinElmer has a 52 week low of $62.91 and a 52 week high of $162.70. The business’s 50-day moving average is $148.84 and its 200 day moving average is $133.07. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.96 and a current ratio of 1.35.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 7th. Investors of record on Friday, April 16th will be issued a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.22%. The ex-dividend date is Thursday, April 15th. PerkinElmer’s dividend payout ratio is presently 6.83%.
PerkinElmer Company Profile
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.